

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

November 21, 2014
(Date of earliest event reported)

**LABORATORY CORPORATION OF
AMERICA HOLDINGS**

(Exact Name of Registrant as Specified in its Charter)

Delaware

1-11353

13-3757370

(State or other jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

358 South Main Street,

Burlington, North Carolina

27215

336-229-1127

(Address of principal executive offices)

(Zip Code)

(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

On November 21, 2014, Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced the completion of its acquisition of LIPOSCIENCE, Inc. (NASDAQ: LPDX), effective November 20, 2014.

At a special meeting held on November 20, 2014, LIPOSCIENCE's stockholders approved the acquisition and the transaction closed promptly thereafter. After the close of the Nasdaq Global Market on November 20, 2014, trading in LIPOSCIENCE common stock ceased, and the listing of LIPOSCIENCE's common stock was suspended. LIPOSCIENCE stockholders will receive a letter of transmittal from Computershare Trust Company, N.A. as paying agent with instructions on how to cash in their shares of LIPOSCIENCE common stock.

Exhibits

99.1 Press Release dated November 21, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

Registrant

By: /s/ F. SAMUEL EBERTS III
F. Samuel Eberts III
Chief Legal Officer and Secretary

November 21, 2014

Exhibit 99.1

FOR IMMEDIATE RELEASE

Investor Inquiries: Stephen Anderson 336-436-5076

Media Inquiries: 336-436-8263

Company Information: www.labcorp.com

358 South Main Street
Burlington, NC 27215
Telephone: (336) 584-5171

LABCORP COMPLETES ACQUISITION OF LIPOSCIENCE

Burlington, NC, November 21, 2014 - Laboratory Corporation of America[®] Holdings (LabCorp[®]) (NYSE: LH) today announced the completion of its acquisition of LIPOSCIENCE, Inc. (NASDAQ: LPDX), effective November 20, 2014.

At a special meeting held on November 20, 2014, LIPOSCIENCE's stockholders approved the acquisition and the transaction closed promptly thereafter. After the close of the Nasdaq Global Market on November 20, 2014, trading in LIPOSCIENCE common stock ceased, and the listing of LIPOSCIENCE's common stock was suspended. LIPOSCIENCE stockholders will receive a letter of transmittal from Computershare Trust Company, N.A. as paying agent with instructions on how to cash in their shares of LIPOSCIENCE common stock.

About LabCorp[®]

Laboratory Corporation of America[®] Holdings, an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of \$5.8 billion in 2013, over 34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more than 4,000 tests ranging from routine blood analyses to reproductive genetics to companion diagnostics. LabCorp furthers its scientific expertise and innovative clinical testing technology through its LabCorp Specialty Testing Group: The Center for Molecular Biology and Pathology, National Genetics Institute, ViroMed Laboratories, Inc, The Center for Esoteric Testing, Litholink Corporation, Integrated Genetics, Integrated Oncology, Dianon Pathology, Monogram Biosciences, Inc, Colorado Coagulation, Cellmark Forensics, MedTox, and Endocrine Sciences. LabCorp conducts clinical trials testing through its LabCorp Clinical Trials division. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our organization, visit our website at: www.labcorp.com.

This press release contains forward-looking statements including with respect to estimated 2014 guidance and the impact of various factors on operating results. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payers. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp's operating and financial results is included in the Company's Form 10-K for the year ended December 31, 2013, including under the heading risk factors, and in the Company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the Company's filings with the SEC including the information in the section of the Company's Form 10-K for the year ended December 31, 2013 and subsequent Forms 10-Q under the heading MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.